Published in Neuron on November 22, 2006
Retracted Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell (2011) 5.09
RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron (2013) 4.67
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell (2011) 3.78
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A (2010) 2.85
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell (2014) 2.63
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Genetic analysis of pathways to Parkinson disease. Neuron (2010) 2.15
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Genetics of Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.96
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
Regulation of the autophagy protein LC3 by phosphorylation. J Cell Biol (2010) 1.86
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet (2010) 1.81
Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet (2011) 1.68
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci (2009) 1.64
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci (2007) 1.59
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A (2007) 1.58
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res (2008) 1.54
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A (2014) 1.53
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet (2011) 1.49
Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry (2010) 1.47
Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord (2007) 1.44
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci (2009) 1.42
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res (2009) 1.38
Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models. Methods Enzymol (2009) 1.36
Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem (2009) 1.36
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis (2010) 1.35
LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci (2010) 1.35
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet (2012) 1.29
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
Update on the pathogenesis of Parkinson's disease. J Neurol (2008) 1.27
A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord (2010) 1.23
Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet (2009) 1.22
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem (2011) 1.22
G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet (2012) 1.21
Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol (2012) 1.16
A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics (2010) 1.15
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain (2015) 1.12
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J (2012) 1.11
Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol (2009) 1.11
Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol (2008) 1.11
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One (2012) 1.10
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med (2012) 1.10
LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet (2011) 1.08
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci (2014) 1.08
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ (2012) 1.07
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav (2007) 1.07
Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration. Front Cell Neurosci (2014) 1.07
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Genetics and genomics of Parkinson's disease. Genome Med (2014) 1.04
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun Integr Biol (2010) 1.04
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci (2012) 1.04
Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.04
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis (2010) 1.03
RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics (2007) 1.03
Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet (2010) 1.03
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem (2010) 1.02
Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun (2014) 1.02
Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci (2014) 1.01
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front Mol Neurosci (2014) 1.01
Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal (2010) 1.01
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis (2011) 0.99
ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One (2010) 0.98
Coordinate Regulation of Neurite Outgrowth by LRRK2 and Its Interactor, Rab5. Exp Neurobiol (2010) 0.98
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet (2014) 0.98
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis (2015) 0.97
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem (2013) 0.97
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
Adult neurogenesis in neurodegenerative diseases. Cold Spring Harb Perspect Biol (2015) 0.96
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One (2010) 0.96
Dysregulation of protein trafficking in neurodegeneration. Mol Neurodegener (2014) 0.95
Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. Hum Mol Genet (2013) 0.95
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord (2011) 0.95
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
A MicroRNA feedback circuit in midbrain dopamine neurons. Science (2007) 8.33
Retracted Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell (2011) 5.09
RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron (2013) 4.67
High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum (2003) 4.36
Retracted Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. Nature (2013) 3.35
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell (2009) 2.60
DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol (2004) 2.51
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron (2003) 2.49
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol (2010) 2.06
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci U S A (2006) 1.69
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Exhaled nitric oxide as a marker of airway inflammation for an epidemiologic study in schoolchildren. J Allergy Clin Immunol (2004) 1.52
Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol (2005) 1.49
Lung transplant waitlist mortality: height as a predictor of poor outcomes. Pediatr Transplant (2014) 1.41
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer (2009) 1.32
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis (2005) 1.30
Midbrain dopamine neuron differentiation: factors and fates. Dev Biol (2007) 1.29
High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem (2003) 1.27
Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat Commun (2012) 1.22
Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol (2008) 1.19
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegener (2012) 1.10
Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders. Neuron (2013) 1.05
Light-driven ion-translocating rhodopsins in marine bacteria. Trends Microbiol (2015) 0.99
Parkinson's disease: Mitochondrial damage control. Nature (2010) 0.97
Parkinson's disease: pro-survival effects of PINK1. Nature (2007) 0.96
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med (2009) 0.96
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res (2011) 0.95
Sonic hedgehog is a chemoattractant for midbrain dopaminergic axons. PLoS One (2009) 0.95
[Splenic metastasis of lung cancer]. Nihon Kokyuki Gakkai Zasshi (2009) 0.94
Tetramer formation kinetics in the signaling state of AppA monitored by time-resolved diffusion. Biophys J (2006) 0.92
In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol Res (2002) 0.91
Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther (2011) 0.91
A blue-shifted light-driven proton pump for neural silencing. J Biol Chem (2013) 0.89
Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Biochem Biophys Res Commun (2003) 0.88
Characterization of a signaling complex composed of sensory rhodopsin I and its cognate transducer protein from the eubacterium Salinibacter ruber. Biochemistry (2009) 0.88
Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood (2006) 0.87
FTIR spectroscopy of a light-driven compatible sodium ion-proton pumping rhodopsin at 77 K. J Phys Chem B (2014) 0.87
Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol (2013) 0.86
Impaired spermatogenesis and male fertility defects in CIZ/Nmp4-disrupted mice. Genes Cells (2004) 0.85
Expression of cellular prion-related protein by murine Langerhans cells and keratinocytes. J Dermatol Sci (2002) 0.85
The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons. J Mol Neurosci (2005) 0.84
Effects of chloride ion binding on the photochemical properties of salinibacter sensory rhodopsin I. J Mol Biol (2009) 0.83
Thermal and spectroscopic characterization of a proton pumping rhodopsin from an extreme thermophile. J Biol Chem (2013) 0.82
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther (2011) 0.82
IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol (2013) 0.82
Spectroscopic studies of a sensory rhodopsin I homologue from the archaeon Haloarcula vallismortis. Biochemistry (2010) 0.81
Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway. PLoS Genet (2013) 0.80
Therapeutic effect of sentinel lymph node biopsy in melanoma remains an open question. J Clin Oncol (2009) 0.80
Energetics and role of the hydrophobic interaction during photoreaction of the BLUF domain of AppA. J Phys Chem B (2008) 0.79
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One (2013) 0.79
Chimeric microbial rhodopsins containing the third cytoplasmic loop of bovine rhodopsin. Biophys J (2011) 0.79
Infrared imaging of an A549 cultured cell by a vibrational sum-frequency generation detected infrared super-resolution microscope. Opt Express (2010) 0.78
Role of trimer-trimer interaction of bacteriorhodopsin studied by optical spectroscopy and high-speed atomic force microscopy. J Struct Biol (2013) 0.78
Progressive disseminated histoplasmosis in an immunocompetent patient as an underrecognized imported mycosis in Japan. J Infect Chemother (2010) 0.78
Synthesis of Pd complexes directly linked to the light-absorbing [(bpy)(3)Ru](2+) unit and their photochemical reactions toward styrenes. Dalton Trans (2008) 0.78
The photochemistry of sodium ion pump rhodopsin observed by watermarked femto- to submillisecond stimulated Raman spectroscopy. Phys Chem Chem Phys (2016) 0.77
[Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients]. Gan To Kagaku Ryoho (2012) 0.77
Transient dissociation of the transducer protein from anabaena sensory rhodopsin concomitant with formation of the M state produced upon photoactivation. J Am Chem Soc (2011) 0.77
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther (2011) 0.77
L105K mutant of proteorhodopsin. Biochemistry (2012) 0.75
IR super-resolution microspectroscopy and its application to single cells. Curr Pharm Biotechnol (2013) 0.75
Dual emission caused by ring inversion isomerization of a 4-methyl-2-pyridyl-pyrimidine copper(I) complex. J Am Chem Soc (2010) 0.75
[The efficacy of influenza vaccine for acute exacerbation of chronic obstructive lung disease in elderly patients]. Nihon Kokyuki Gakkai Zasshi (2008) 0.75
[Effectiveness of inhaled corticosteroids (ics) combination therapy; the addition of qvar to flutide]. Arerugi (2008) 0.75
[Osteopontin in rheumatoid arthritis]. Nihon Rinsho (2005) 0.75
Unique Hydrogen Bonds in Membrane Protein Monitored by Whole Mid-IR ATR Spectroscopy in Aqueous Solution. J Phys Chem B (2017) 0.75
DNA microarrays detect effects of soil contamination on Arabidopsis thaliana gene expression. Environ Toxicol Chem (2008) 0.75
[The development of single molecular method for the study on the signal transduction mechanism of microbial rhodopsins]. Seikagaku (2014) 0.75
The effect of pretensioning and age on torso rollout in restrained human volunteers in far-side lateral and oblique loading. Stapp Car Crash J (2012) 0.75
Retraction Notice to: Directed Conversion of Alzheimer's Disease Patient Skin Fibroblasts into Functional Neurons. Cell (2014) 0.75